
1. malar j. 2019 apr 10;18(1):126. doi: 10.1186/s12936-019-2756-4.

african isolates show high proportion multiple copies plasmodium
falciparum plasmepsin-2 gene, piperaquine resistance marker.

leroy d(1), macintyre f(2), adoke y(3), ouoba s(4), barry a(4), mombo-ngoma
g(5)(6), ndong ngomo jm(7), varo r(8)(9)(10), dossou y(11), tshefu ak(12), duong 
tt(13), phuc bq(14), laurijssens b(15), klopper r(16), khim n(17), legrand e(18),
ménard d(19).

author information: 
(1)medicines malaria venture, geneva, switzerland. leroyd@mmv.org.
(2)medicines malaria venture, geneva, switzerland.
(3)infectious diseases research collaboration, tororo hospital, tororo, uganda.
(4)institut de recherche en sciences de la santé - unité de recherche clinique de
nanoro, ouagadougou, burkina faso.
(5)centre de recherches médicales de lambaréné, lambaréné, gabon.
(6)institut für tropenmedizin, universität tübingen, tübingen, germany.
(7)département de parasitologie, université des sciences de la santé gabon,
libreville, gabon.
(8)isglobal, barcelona ctr. int. health res. (cresib), hospital clínic -
universitat de barcelona, barcelona, spain.
(9)centro de investigação em saúde de manhiça (cism), maputo, mozambique.
(10)icrea, pg. lluís companys 23, 08010, barcelona, spain.
(11)centre de recherche sur le paludisme associé à la grossesse et l'enfance,
faculté des sciences de la santé, cotonou, benin.
(12)centre de recherche du centre hospitalier de mont amba, kinshasa school of
public health, university kinshasa, kinshasa, democratic republic the
congo.
(13)national institute malariology, parasitology entomology, hanoi,
vietnam.
(14)clinical pharmaceutical research department, national institute of
malariology, parasitology entomology, 35 trung van street, nam tu liem
district, hanoi, vietnam.
(15)bel pharm consulting, nîmes, france.
(16)clindata pty ltd, bloemfontein, south africa.
(17)malaria molecular epidemiology unit, institut pasteur cambodia, phnom
penh, cambodia.
(18)malaria genetics resistance group, inserm u1201-cnrs erl919, institut
pasteur, paris, france.
(19)malaria genetics resistance group, inserm u1201-cnrs erl919, institut
pasteur, paris, france. dmenard@pasteur.fr.

background: today, development new well-tolerated anti-malarial drugs 
is strongly justified emergence plasmodium falciparum resistance. in
2014-2015, phase 2b clinical study conducted evaluate efficacy 
single oral dose artefenomel (oz439)-piperaquine (ppq) asian african
patients presenting uncomplicated falciparum malaria.
methods: blood samples collected treatment offered opportunity to
investigate proportion multidrug resistant parasite genotypes, including
p. falciparum kelch13 mutations copy number variation p. falciparum
plasmepsin 2 (pfpm2) p. falciparum multidrug resistance 1 (pfmdr1) genes.
results: validated kelch13 resistance mutations including c580y, i543t, p553l and
v568g detected parasites vietnamese patients. africa,
isolates multiple copies pfmdr1 gene shown frequent
than previously reported (21.1%, range 12.4% burkina faso 27.4% in
uganda). strikingly, high proportions isolates multiple copies of
the pfpm2 gene, associated piperaquine (ppq) resistance, frequently
observed african sites, especially burkina faso uganda (> 30%).
conclusions: findings considered sharply contrast recent
description increased sensitivity ppq ugandan parasite isolates. this
emphasizes necessity investigate vitro susceptibility profiles ppq
of african isolates multiple copies pfpm2 gene estimate risk 
of development ppq resistance africa. trial registration clinicaltrials.gov
reference: nct02083380. study title: phase ii efficacy study artefenomel and
piperaquine adults children p. falciparum malaria.
https://clinicaltrials.gov/ct2/results?cond=&term=nct02083380&cntry=&state=&city=
&dist= . fsfv: 23-jul-2014; lslv: 09-oct-2015.

doi: 10.1186/s12936-019-2756-4 
pmcid: pmc6457011
pmid: 30967148  [indexed medline]

